The Washington State Health Care Authority has selected AbbVie to supply hepatitis C medication under a subscription-based payment model, the agency announced April 26.
Under the terms of the contract, the state will pay a fixed dollar amount to AbbVie for an unlimited supply of hepatitis C drugs.
The contract is part of the state's plan to eliminate hepatitis C by 2030.
Last month, the state of Louisiana struck a deal with a Gilead Sciences subsidiary to supply hepatitis C medication under a subscription-style payment model.
Both Washington and Louisiana plan to start their programs this summer.